



09.30.2012

INTERIM REPORT

## PROFILE

STRATEC DEVELOPS AND MANUFACTURES FULLY AUTOMATED ANALYZER SYSTEMS BASED ON ITS OWN PATENTED TECHNOLOGIES FOR ITS PARTNERS IN THE FIELDS OF CLINICAL DIAGNOSTICS AND BIOTECHNOLOGY. STRATEC'S PARTNERS ARE MOSTLY GLOBAL PLAYERS OPERATING IN THE IN-VITRO DIAGNOSTICS INDUSTRY. THESE COMPANIES MARKET STRATEC'S SYSTEMS UNDER THEIR OWN NAMES, IN GENERAL TOGETHER WITH THEIR OWN REAGENTS, AS SYSTEM SOLUTIONS TO LABORATORIES, BLOOD BANKS, AND RESEARCH INSTITUTES AROUND THE WORLD.

## CONTENTS

- 03 HIGHLIGHTS / KEY GROUP FIGURES AT A GLANCE
- 04 FOREWORD BY THE BOARD OF MANAGEMENT
- 05 INTERIM GROUP MANAGEMENT REPORT
- 09 CONSOLIDATED BALANCE SHEET  
as of September 30, 2012
- 11 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME  
(total cost method) for the Period from July 1 to September 30, 2012
- 12 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME  
(total cost method) for the Period from January 1 to September 30, 2012
- 13 CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME  
(cost of sales method) for the Period from January 1 to September 30, 2012
- 14 CONSOLIDATED CASH FLOW STATEMENT  
for the Period from January 1 to September 30, 2012
- 15 CONSOLIDATED STATEMENT OF CHANGES IN EQUITY  
for the Period from January 1 to September 30, 2012
- 17 NOTES TO THE GROUP INTERIM REPORT  
for the Period from January 1 to September 30, 2012
- 20 ADDITIONAL INFORMATION

## HIGHLIGHTS

Sales of €87.6 million in 9M/2012  
(+9.3%; 9M/2011: €80.2 million)

EBIT margin of 15.3% in 9M/2012  
(9M/2011: 18.8%)

Consolidated net income of €10.9 million in 9M/2012  
(+10.4%; 9M/2011: €9.8 million)

Earnings per share of €0.93 in 9M/2012  
(+9.4%; 9M/2011: €0.85)

2012 forecast specified: Sales of €120 million  
to €125 million/EBIT margin of 14% to 16%

## KEY GROUP FIGURES AT A GLANCE

in € thousands	01.01.-09.30.2012**	01.01.-09.30.2011*	Change
Sales	87,584	80,155	+9.3%
Overall performance	92,379	85,871	+7.6%
EBITDA	16,333	17,636	-7.4%
EBIT	13,357	15,065	-11.3%
EBIT margin (%)	15.3	18.8	-
Consolidated net income	10,865	9,840	+10.4%
Earnings per share (€)	0,93	0,85	+9.4%
No. of employees (absolute)	524	484	+8.3%

in € thousands	09.30.2012	12.31.2011	Change
Shareholders' equity	88,764	83,231	+6.6%
Total assets	119,154	110,997	+7.3%
Equity ratio (%)	74.5	75.0	-

\* 2011: The figures are presented in the table on an unadjusted basis. Adjusted for a one-off item of €1.6 million resulting from a routine tax audit for the financial years 2005 to 2008, consolidated net income for the first nine-months of 2011 would amount to €11.4 million and earnings per share would amount to €0.99.

\*\* 2012: The figures are presented in the table on an unadjusted basis. Adjusted for a one-off item of €3.3 million incurred in the first quarter of 2012 due to the income-neutral reclassification of unfinished services and prepayments received due to the impairment

## FOREWORD BY THE BOARD OF MANAGEMENT

### Dear Shareholders,

The third quarter of 2012 and the usually very strong month of September were characterized this year by starkly contrasting developments. On the one hand, very positive progress was made with new projects and promising advances were seen in the field of business development (new projects). On the other hand, our operating business performance was disappointing, with very weak sales reported for maintenance and replacement materials. At STRATEC, this consumables business in particular plays a key role in determining the development in the company's margins.

When comparing the sales performance for 2011 and 2012, two one-off, non-operating factors have to be considered. On the one hand, in 2011 we posted a tax back payment of € 1.6 million for the fiscal years 2005 to 2008, with a correspondingly negative impact on earnings. On the other hand, in the first quarter of 2012 the write-down of a development project resulted in the posting of an additional item increasing our sales by € 3.3 million. Net of these two items, we increased our nine-month sales by 5.3% from € 80.2 million to € 84.3 million (unadjusted: € 87.6 million / +9.3%). At € 13.4 million, our EBIT as of September 30, 2012 was 11.3% down on the equivalent figure of € 15.1 million for the previous year. At € 10.9 million, consolidated net income was 10.4% ahead of the previous year's figure of € 9.8 million. Having said this, the previous year's figure had been negatively affected by the aforementioned tax back payment.

We intend to issue a status update before the end of the current financial year. In this, we will provide an overview of those current and new projects that will play a significantly positive role in driving our growth in the years after 2014.

Even though the developments seen in the third quarter were not foreseeable and could therefore not have been planned, in our talks with customers we are nevertheless endeavoring to further enhance the forecastability of their orders, especially for consumables, and to factor this information into our forecast system where possible. This is important not only to ensure the smooth course of business operations, but also to assist us in our internal planning. Ultimately, it also forms an important part of our communications with our partners and shareholders, whose trust we see as representing one of the foundations of our success.

Birkenfeld, October 2012

The Board of Management of  
STRATEC Biomedical AG



Marcus Wolfinger



Dr. Robert Siegle



Bernd M. Steidle

# INTERIM GROUP MANAGEMENT REPORT

## REPORT ON THE EARNINGS, FINANCIAL AND NET ASSET POSITION

Sales for the first nine months of the 2012 financial year grew by 9.3% to € 87.6 million (previous year: € 80.2 million). Despite the reclassification within equity of a milestone payment, the overall performance rose by 7.6% to € 92.4 million (previous year: € 85.9 million). The cost of materials increased over the same period by 11.2% from € 40.8 million to € 45.4 million.

Alongside the further expansion in production capacities, the stepping up of development activities in particular led personnel expenses to rise from € 21.2 million to € 24.8 million.

Due to cost-cutting measures, other operating expenses could be reduced to € 6.7 million, down from € 7.2 million in the previous year. Depreciation and amortization increased to € 3.0 million. Net financial expenses improved from € -0.4 million in the previous year to € 0.0 million. STRATEC thus boosted its consolidated net income for the period under report to € 10.9 million (previous year: € 9.8 million), corresponding to earnings per share of € 0.93 (previous year: € 0.85).

Due to the forthcoming market launches of two analyzer systems and the increase in development services, inventories rose by € 8.1 million. Total receivables and other assets increased from € 23.1 million to € 27.7 million. As a result of the dividend payment and the increase in inventories, cash and cash equivalents declined from € 19.5 million to € 14.1 million, and that despite a positive cash flow of € 2.0 million from operating activities.

The equity ratio amounts to 74.5%. Non-current financial liabilities could be reduced to € 9.4 million. The increase in trade payables was driven by higher procurement volumes for raw materials and supplies. Within other current liabilities, an amount of around € 8.6 million has been reported for prepayments received for development services.

The inflow of funds from operating activities fell to € 2.0 million, down from € 5.8 million in the previous year. The STRATEC Group invested € 1.3 million in the first nine months of the 2012 financial year (previous year: € 2.1 million; previous year's figure includes construction activities of € 0.5 million).

## CHANGES IN THE BUSINESS ENVIRONMENT AND IMPLICATIONS FOR STRATEC

Against the backdrop of the Euro crisis and the protracted political contest in the USA, in its latest forecast dated October 2012 the International Monetary Fund (IMF) has painted a pessimistic picture of the global economy and issued further downward corrections in its growth forecast for the global economy in the current and next years.

For the global economy, the IMF has now forecast growth of 3.3% in the current year, and 3.6% next year. Compared with the previous growth forecast issued in July 2012, these figures have thus been cut by 0.2 and 0.3 percentage points respectively.

The USA is forecast to post the strongest growth among the industrialized economies, with growth of 2.2% in 2012 and of 2.1% in 2013. The IMF has cut its forecast for economic developments in the euro area by 0.1% to minus 0.4% for the current year, and by 0.5% to now just 0.2% for 2013. The IMF also reduced its estimates for emerging economies such as Brazil, China and India.

According to the IMF, this deterioration in the outlook is due in particular to uncertainties in the markets. Furthermore, it was currently very difficult for investors to predict how the situation would develop in the coming months. Given the large number of imponderables, there was even the risk that global growth could fall short of 2.0%. The probability of this occurring currently amounted to 17% and had risen since the previous forecast.

Global demographic developments represent one of the most serious challenges facing the world. The dynamic growth in the world's population, together with an unprecedented increase in the elderly share of the population and the sharp rise in the number of people with access to medical care, represent key factors which will shape the 21<sup>st</sup> century. This situation is accompanied by scientific and technological progress, which is opening up ever new possibilities in the fields of medicine, research, diagnostics and life science.

These developments will lead not only to an increase in the numbers of clinical diagnostics tests to be performed, but will also result in new, unique business opportunities for which STRATEC is optimally positioned with its automation solutions and on which it will continue to focus its strategy and operations.

In view of the factors outlined above, global economic risks only have a very limited impact on STRATEC's business performance and business model. Moreover, long-term supply agreements with our customers minimize the potential implications of the crisis for STRATEC.

## REPORT ON FORECASTS AND OTHER STATEMENTS CONCERNING THE COMPANY'S EXPECTED DEVELOPMENT

Upon publication of its preliminary figures on October 18, 2012, STRATEC simultaneously lowered its forecast for the current year. The company now expects to generate sales of between € 120 million and € 125 million rather than the previously forecast range of € 125 million to € 139 million.

Sales growth will mainly be driven by growth with systems already established in the market. Unlike originally planned, two new systems due to be presented to the public by our customers in November will then only make a very small contribution to this year's growth. Order behavior for maintenance and spare parts has stabilized at the low level seen, on average, in the first nine months.

Several key factors will play a significant role in influencing the future development in our EBIT margin. These factors include the gross margin generated with new systems and the volume of investment in development activities. These factors are capable of being actively influenced with suitable measures. To enhance the gross margin we have, as is customary following new market launches, begun implementing a program aimed at optimizing production and supply chain processes. Given the need to achieve the fastest possible market launch, these aspects do not receive full consideration during the development stage and therefore harbor potential for optimization. Investments in development activities, also at subsidiaries, are made almost exclusively with a view to initiating the next growth phase. These factors thus contrast with our customers' order and call-up behavior. While analyzer systems orders involve a corresponding lead time and a forecast system with up to 12 months' advance warning is in place, orders for spare parts and maintenance materials are made at very short notice. Although we are making efforts to put similar forecast models in place, our customers are only able to make limited concessions in this area. This is because demand for these materials is closely linked to capacity utilization rates on location in hospitals, laboratories and blood banks and therefore cannot be predicted to any adequate extent.

As already mentioned, events in the third quarter mean that our short-term sales and earnings outlook through to the end of 2012 is highly reserved. Based on sales of between € 120 million to € 125 million, we expect to generate an EBIT margin of between 14% and 16%.

The company forecast is planned to be updated around the time of publication of the 2012 Annual Report in April 2013. For 2012 to 2014, we are upholding our forecast of expected average sales growth of 14% to 16% based on the 2011 sales figure (€ 116.6m). Accordingly, sales of € 151 million to € 157 million could be



expected in 2013. The achievement or exceeding of this range is dependent on the performance of the systems newly launched onto the market at the end of 2012 and on follow-up approvals, as well as on the further progress made with development projects and associated reclassifications from milestone payments to sales. In terms of our costs, margins will continue to be held back by investments in new development programs. In the medium term, however, the margin is expected to recover due to benefits of scale arising in particular from the higher expected share of sales generated with maintenance and spare parts.

Due to the immense debt accumulated by some countries and economic regions and the resultant potential implications (debt crisis), the level of budgeting reliability remains low for all industries, and for the global economy as a whole. This situation continues to harbor risks for STRATEC's customers and suppliers, as a result of which STRATEC also faces economic risks. The ongoing difficult economic climate also means that STRATEC continues to face increased market risk.

Apart from this, since the assessment of the company's situation provided on March 12, 2012 upon the compilation of the Annual Report for the 2011 financial year, no new information has arisen which could lead to any change in our assessment of the company's expected development.

## OPPORTUNITY AND RISK REPORT

We analyze and evaluate the risks facing the company and its business environment within the framework of our risk management system, which has been established as an early warning risk identification system. Furthermore, this system also includes a compliance system to ensure compliance with the relevant legal and industry-specific requirements.

STRATEC's business activities basically focus on sustainability and responsible behavior. In future, the company will document this in a sustainability report.

Apart from the factors outlined in the "Report on forecasts and other statements concerning the company's expected development", we do not see any changes compared with the risks and opportunities identified in the Group Management Report for the 2011 financial year dated March 12, 2012. Reference is made to the "Risk Report" section within the 2011 Group Management Report for details concerning our risk management system and our company's specific opportunity and risk profile.

# CONSOLIDATED BALANCE SHEET

as of September 30, 2012  
of STRATEC Biomedical AG

ASSETS in € thousands	09.30.2012	12.31.2011
<b>NON-CURRENT ASSETS</b>		
Goodwill	4,611	4,584
Other intangible assets	6,188	5,874
Property, plant and equipment	17,113	17,212
Interests in associates	394	351
Deferred tax assets	1,187	630
	<b>29,493</b>	<b>28,651</b>
<b>CURRENT ASSETS</b>		
Raw materials and supplies	13,096	8,269
Unfinished products, unfinished services	33,229	30,409
Finished products and goods	1,199	774
Trade receivables	18,051	15,331
Future receivables from construction contracts	6,066	5,992
Receivables from associates	86	122
Other receivables and other assets	3,540	1,679
Securities	269	222
Cash and cash equivalents	14,125	19,548
	<b>89,661</b>	<b>82,346</b>
<b>TOTAL ASSETS</b>	<b>119,154</b>	<b>110,997</b>

SHAREHOLDERS' EQUITY AND DEBT in € thousands	09.30.2012	12.31.2011
<b>SHAREHOLDERS' EQUITY</b>		
Share capital	11,736	11,675
Capital reserve	16,166	15,306
Revenue reserves	48,965	40,098
Consolidated net income	10,865	15,282
Other equity	1,032	870
	<b>88,764</b>	<b>83,231</b>
<b>DEBT</b>		
<b>Non-current debt</b>		
Non-current financial liabilities	8,163	9,167
Deferred taxes	1,242	1,352
	<b>9,405</b>	<b>10,519</b>
<b>Current debt</b>		
Current financial liabilities	1,256	777
Trade payables	5,636	3,955
Liabilities to associates	313	40
Other current liabilities	11,739	10,314
Current provisions	1,386	1,427
Income tax liabilities	655	710
	<b>20,985</b>	<b>17,223</b>
<b>Deferred income and accrued expenses</b>	<b>0</b>	<b>24</b>
<b>TOTAL SHAREHOLDERS' EQUITY AND DEBT</b>	<b>119,154</b>	<b>110,997</b>

# CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME \*

for the Period from July 1 to September 30, 2012  
of STRATEC Biomedical AG

in € thousands	07.01.-09.30.2012	07.01.-09.30.2011
<b>Sales</b>	<b>29,342</b>	<b>31,764</b>
Change in volume of finished and unfinished products and unfinished services	1,437	-959
Other own work capitalized	730	422
<b>Overall performance</b>	<b>31,509</b>	<b>31,227</b>
Other operating income	200	648
Cost of raw materials and supplies	15,721	14,800
Cost of purchased services	837	539
Personnel expenses	8,188	7,157
Other operating expenses	2,073	2,470
<b>EBITDA</b>	<b>4,890</b>	<b>6,909</b>
Amortization of intangible assets and depreciation of property, plant and equipment	957	899
<b>EBIT</b>	<b>3,933</b>	<b>6,010</b>
Net financial expenses	99	-191
<b>Operating result (EBT)</b>	<b>4,032</b>	<b>5,819</b>
Current tax expenses	570	2,926
Deferred tax income (previous year: deferred tax expenses)	51	103
<b>Consolidated net income</b>	<b>3,513</b>	<b>2,790</b>
<b>Income and expenses recognized directly in equity (after taxes)</b>		
Hedging transactions	54	0
Currency translation of foreign financial statements	28	419
<b>Comprehensive income</b>	<b>3,595</b>	<b>3,209</b>
<b>Earnings per share in €</b>	<b>0.30</b>	<b>0.24</b>
Number of shares used as basis	11,701,548	11,647,143
<b>Earnings per share, diluted, in €</b>	<b>0.30</b>	<b>0.24</b>
Number of shares used as basis, diluted	11,737,403	11,705,207

\*Figures presented derived using total cost method.

# CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME \*

for the Period from January 1 to September 30, 2012  
of STRATEC Biomedical AG

in € thousands	01.01.-09.30.2012	01.01.-09.30.2011
<b>Sales</b>	<b>87,584</b>	<b>80,155</b>
Change in volume of finished and unfinished products and unfinished services	3,095	4,554
Other own work capitalized	1,700	1,162
<b>Overall performance</b>	<b>92,379</b>	<b>85,871</b>
Other operating income	825	899
Cost of raw materials and supplies	43,417	39,470
Cost of purchased services	1,933	1,298
Personnel expenses	24,798	21,230
Other operating expenses	6,723	7,136
<b>EBITDA</b>	<b>16,333</b>	<b>17,636</b>
Amortization of intangible assets and depreciation of property, plant and equipment	2,976	2,571
<b>EBIT</b>	<b>13,357</b>	<b>15,065</b>
Net financial expenses	-28	-356
<b>Operating result (EBT)</b>	<b>13,329</b>	<b>14,709</b>
Current tax expenses	3,178	5,190
Deferred tax income	714	321
<b>Consolidated net income</b>	<b>10,865</b>	<b>9,840</b>
<b>Income and expenses recognized directly in equity (after taxes)</b>		
Hedge transactions *	-27	0
Currency translation of foreign financial statements	190	-140
<b>Comprehensive income</b>	<b>11,028</b>	<b>9,700</b>
<b>Earnings per share in €</b>	<b>0.93</b>	<b>0.85</b>
Number of shares used as basis	11,679,231	11,600,546
<b>Earnings per share, diluted, in €</b>	<b>0.93</b>	<b>0.84</b>
Number of shares used as basis, diluted	11,738,467	11,706,526

\* Figures presented derived using total cost method. The supplementary presentation based on the cost of sales method and provided solely for information reasons can be found on Page 13.

# CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME \*

for the Period from January 1 to September 30, 2012  
of STRATEC Biomedical AG

in € thousands	01.01.-09.30.2012	01.01.-09.30.2011
<b>Sales</b>	<b>87,584</b>	<b>80,155</b>
Cost of sales	59,812	52,808
<b>Gross profit</b>	<b>27,772</b>	<b>27,347</b>
Research and development expenses	5,781	5,066
Information only: Capitalized research and development expenses	10,593	9,257
Information only: Total research and development expenses	16,374	14,323
Distribution costs	3,841	3,581
General administrative expenses	4,633	4,176
Other operating income	762	1,495
Other operating expenses	922	954
<b>EBIT</b>	<b>13,357</b>	<b>15,065</b>
Net financial expenses	-28	-356
<b>Operating result (EBT)</b>	<b>13,329</b>	<b>14,709</b>
Current tax expenses	3,178	5,190
Deferred tax income	714	321
<b>Consolidated net income</b>	<b>10,865</b>	<b>9,840</b>
<b>Income and expenses recognized directly in equity (after taxes)</b>		
Hedging transactions	-27	0
Currency translation of foreign financial statements	190	-140
<b>Comprehensive income</b>	<b>11,028</b>	<b>9,700</b>
<b>Earnings per share in €</b>	<b>0.93</b>	<b>0.85</b>
Number of shares used as basis	11,679,231	11,600,546
<b>Earnings per share, diluted, in €</b>	<b>0.93</b>	<b>0.84</b>
Number of shares used as basis, diluted	11,738,467	11,706,526

\* Figures presented derived using the cost of sales method. This disclosure is to be viewed as a supplement to, rather than as a substitute for the statement of comprehensive income using the total cost method. This disclosure does not form part of the respective accounting requirements.

# CONSOLIDATED CASH FLOW STATEMENT

for the Period from January 1 to September 30, 2012  
of STRATEC Biomedical AG

in € thousands	01.01.-09.30.2012	01.01.-09.30.2011
Consolidated net income (after taxes)	10,865	9,840
Depreciation and amortization	2,976	2,571
Current income tax expenses	3,178	3,592
Income taxes paid less income taxes received	-4,492	-4,132
Financial income	-174	-121
Financial expenses	206	477
Interest paid	-158	-246
Interest received	156	91
Other non-cash expenses	222	556
Other non-cash income	-1,873	-1,162
<b>Cash flow</b>	<b>10,906</b>	<b>11,466</b>
Change in deferred taxes through profit or loss	-714	-321
Profit from disposal of non-current assets	-21	-121
Increase in inventories, trade receivables and other assets	-11,481	-12,490
Increase in trade payables and other liabilities	3,314	7,275
<b>Inflow of funds from operating activities</b>	<b>2,004</b>	<b>5,809</b>
Incoming payments from disposals of non-current assets		
Property, plant and equipment	50	152
Outgoing payments for investments in non-current assets		
Intangible assets	-204	-155
Property, plant and equipment	-1,112	-1,965
Prepayments made / assets under construction	-28	-136
Financial assets	-30	0
<b>Outflow of funds for investment activities</b>	<b>-1,324</b>	<b>-2,104</b>
Incoming payments from taking up of financial liabilities	77	2,515
Outgoing payments for repayment of financial liabilities	-612	-529
Incoming payments for issues of shares for employee stock option programs	820	1,355
Dividend payment	-6,415	-5,778
<b>Outflow of funds for financing activities</b>	<b>-6,130</b>	<b>-2,437</b>
<b>Cash-effective change in cash and cash equivalents</b>	<b>-5,450</b>	<b>1,268</b>
<b>Cash and cash equivalents at beginning of period</b>	<b>19,548</b>	<b>13,222</b>
Change in cash and cash equivalents due to changes in exchange rates	27	-320
<b>Cash and cash equivalents at end of period</b>	<b>14,125</b>	<b>14,170</b>

# CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the Period from January 1 to September 30, 2012  
of STRATEC Biomedical AG

## JANUARY - SEPTEMBER 2011

in € thousands	Share capital	Capital reserve	Revenue reserves	
			Accumulated net income	Free revenue reserves
<b>Balance at 01.01.2011</b>	<b>11,569</b>	<b>13,915</b>	<b>22,445</b>	<b>10,540</b>
Dividend payment				
Issue of subscription shares from stock option programs, less costs of capital issue after taxes	103	1,252		
Allocations due to stock option plans		120		
Allocation to free revenue reserves				3,000
Profit carried forward			4,261	
Disposal of treasury stock shares		-148		
Comprehensive income				
<b>Balance at 09.30.2011</b>	<b>11,672</b>	<b>15,139</b>	<b>26,706</b>	<b>13,540</b>

## JANUARY - SEPTEMBER 2012

in € thousands	Share capital	Capital reserve	Revenue reserves	
			Accumulated net income	Free revenue reserves
<b>Balance at 01.01.2012</b>	<b>11,675</b>	<b>15,307</b>	<b>26,706</b>	<b>13,392</b>
Dividend payment				
Issue of subscription shares from stock option programs, less costs of capital issue after taxes	61	759		
Allocations due to stock option plans		100		
Value adjustments recognized directly in equity				
Allocation to free revenue reserves				3,000
Profit carried forward			5,867	
Disposal of treasury stock shares				
Comprehensive income				
<b>Balance at 09.30.2012</b>	<b>11,736</b>	<b>16,166</b>	<b>32,573</b>	<b>16,392</b>



Consolidated net income	Other equity		Group equity
	Treasury stock	Currency translation	
13,039	-417	788	71,879
-5,778			-5,778
			1,355
			120
-3,000			0
-4,261			0
	205		57
9,840		-140	9,700
<b>9,840</b>	<b>-212</b>	<b>648</b>	<b>77,333</b>

Consolidated net income	Other equity			Group equity
	Hedging transactions	Treasury stock	Currency translation	
15,282	0	-212	1,082	83,232
-6,415				-6,415
				820
				100
	-28		190	162
-3,000				0
-5,867				0
				0
10,865				10,865
<b>10,865</b>	<b>-28</b>	<b>-212</b>	<b>1,272</b>	<b>88,764</b>

# NOTES TO THE GROUP INTERIM REPORT

for the period from January 1 to September 30, 2012  
of STRATEC Biomedical AG

## Summary of principal accounting and valuation methods

The consolidated financial statements of STRATEC Biomedical AG as of December 31, 2011 were prepared in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU valid at the balance sheet date. In the interim report as of September 30, 2012, which has been prepared on the basis of International Accounting Standard (IAS) 34 "Interim Financial Reporting", application has been made of the same accounting methods as in the consolidated financial statements for the 2011 financial year.\* Application has also been made of all interpretations of the International Financial Reporting Interpretations Committee (IFRIC) with binding effect as of September 30, 2012.

There were no indications of any potential impairment in goodwill at the balance sheet date.

The company's interim reports are neither audited, nor subject to an audit review, by the group auditor, Wirtschaftstreuhand GmbH Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft, Stuttgart.

Reference is made to the consolidated financial statements of STRATEC Biomedical AG as of December 31, 2011 with regard to further information concerning the individual accounting and valuation methods applied.

The Group's currency is the euro. Unless otherwise indicated, all amounts have been stated in thousand euros (€ thousand).

## Segment disclosures

There have been no changes in the segmentation of the Group's results compared with the consolidated financial statements as of December 31, 2011.

Segment data by operating segment for the period from January 1 to September 30, 2012

in € thousands	Instrumentation	All other segments	Reconciliation	Total
Sales	91,631	2,978	-7,025	87,584
EBITDA	17,482	-1,251	102	16,333
EBIT	15,250	-1,384	-509	13,357
EBT	15,222	-1,394	-499	13,329
Net income	12,389	-1,011	-513	10,865
Assets	133,910	3,613	-18,369	119,154

\*The presentation of the statement of comprehensive income using the cost of sales method is to be viewed as a supplement to, rather than as a substitute for the disclosures presented in accordance with IFRS. This disclosure does not form part of the respective accounting requirements.

Segment data by operating segment for the period from January 1 to September 30, 2011

in € thousands	Instrumentation	All other segments	Reconciliation	Total
Sales	80,323	3,144	-3,312	80,155
EBITDA	17,760	-214	90	17,636
EBIT	15,869	-283	-521	15,065
EBT	15,542	-156	-677	14,709
Net income	10,406	-320	-246	9,840
Assets	123,545	3,740	-14,665	112,620

The breakdown of sales by geographical region represents the distribution of the STRATEC Group's products. As the customers of the STRATEC Group generally supply their country outlets and customers from their own central distribution centers, however, this breakdown of sales does not represent the geographical distribution of the final operating locations of the STRATEC Group's analyzer systems.

Sales can be broken down by geographical regions (customer locations) as follows:

in € thousands	Germany	EU	Other	Total
January - September 2012	12,560	38,954	36,070	<b>87,584</b>
	14.3%	44.5%	41.2%	<b>100.0%</b>
in € thousands	Germany	EU	Other	Total
January - September 2011	14,547	44,197	21,411	<b>80,155</b>
	18.2%	55.1%	26.7%	<b>100.0%</b>

### Research and development expenses

The expenses relating to research and project management, and to development services not fulfilling the capitalization criteria set out in IAS 38, amounted to € 5.8 million in the first nine months of the 2012 financial year (previous year: € 5.1 million). These have been reported, mainly as personnel expenses, in the company's consolidated statement of comprehensive income. Moreover, procurement volumes of around € 0.6 million (previous year: € 0.7 million) were incurred during the period under report in connection with materials used in research and development. These have been included in the cost of materials item. The STRATEC Group invested a total amount of € 16.4 million in research and development in the first nine months of the 2012 financial year (previous year: € 14.3 million). As a percentage of sales (excluding development and services), this corresponds to a ratio of 21.3% (previous year: 20.3%).

### Shareholders' equity

The development in shareholders' equity at the STRATEC Group has been presented in the consolidated statement of changes in equity on Pages 15 and 16. The number of ordinary shares with a nominal value of € 1.00 each issued by STRATEC AG as of September 30, 2012, amounts to 11,735,645. These are all bearer shares.

### Disclosures on the volume of treasury stock and on subscription rights held by members of the company's executive and supervisory bodies and its employees pursuant to § 160 (1) Nos. 2 and 5 of the German Stock Corporation Act (AktG)

STRATEC AG owned a total of 12,223 treasury stock at the interim balance sheet date. This corresponds to a prorated amount of € 12,223.00 of the company's share capital and to a 0.10% share of its equity.

### Stock option programs

Members of the Board of Management / Managing Directors and employees held the following numbers of subscription rights (share option rights) at the interim balance sheet date:

	<b>Board of Management / Managing Directors</b>	<b>Employees</b>	<b>Total</b>
Outstanding on 01.01.2012	102,000	52,150	154,150
Issued	60,000	7,050	67,050
Exercised	55,000	5,750	60,750
Lapsed	0	200	200
Outstanding on 09.30.2012	107,000	53,250	160,250

A total of 7,050 stock option rights were granted to company employees and a total of 60,000 stock option rights to members of the Board of Management on the basis of option agreements dated February 1, 2012, February 23, 2012, May 24, 2012, June 1, 2012 and August 1, 2012.

A total of 55,000 stock option rights were exercised by members of the Board of Management and a total of 5,750 stock option rights by employees in the first nine months of the 2012 financial year. To service these stock option rights, 60,750 shares were created from conditional capital.

Furthermore, 200 stock option rights lapsed in the period under report.

### Employees

Including temporary employees the STRATEC Group had a total workforce of 524 employees as of September 30, 2012 (previous year: 484).

### Major events after the interim reporting date

No events of particular significance with material implications for the business performance of our Group have occurred since the interim balance sheet date.

### Responsibility statement

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the Group, and the interim management report of the Group includes a fair review of the development and performance of the business and the position of the Group, together with a description of the principal opportunities and risks associated with the expected development of the Group in the remainder of the financial year.

## ADDITIONAL INFORMATION

### FINANCIAL CALENDAR

<b>October 24, 2012</b>	Interim Report as of September 30, 2012
<b>November 12, 2012</b>	STRATEC Capital Markets Day, Frankfurt/Main, Germany

Furthermore, based on current planning, STRATEC will be taking part in the following capital market conferences in 2012:

<b>November 2012</b>	German Equity Forum, Frankfurt / Main, Germany
	Jefferies 2012 Global Healthcare Conference, London, UK
	HSBC 5 <sup>th</sup> HealthCare Conference, Frankfurt / Main, Germany

Partially incomplete / subject to amendment

## ABOUT STRATEC

STRATEC Biomedical AG designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE 0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information about STRATEC is available on the internet at [www.stratec.com](http://www.stratec.com).

## IMPRINT

### Published by

STRATEC Biomedical AG  
Gewerbestr. 37  
75217 Birkenfeld  
Germany

Phone: +49 7082 7916-0  
Fax: +49 7082 7916-999  
[info@stratec.com](mailto:info@stratec.com)  
[www.stratec.com](http://www.stratec.com)

### Investor Relations

ANDREAS KÜNZEL  
Phone: +49 7082 7916-185  
Fax: +49 7082 7916-999  
[a.kuenzel@stratec.com](mailto:a.kuenzel@stratec.com)

ANDRE LOY  
Phone: +49 7082 7916-190  
Fax: +49 7082 7916-999  
[a.loy@stratec.com](mailto:a.loy@stratec.com)

### NOTICE

Forward-looking statements involve risks: This interim report contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This interim report contains various disclosures of an economic nature that do not form part of the relevant accounting requirements. These disclosures are to be viewed as a supplement to, rather than as a substitute for the disclosures made in accordance with IFRS.

Discrepancies may arise throughout this interim report on account of mathematical rounding up or down in the course of addition.

This interim report is also available in German.

**STRATEC BIOMEDICAL AG**

Gewerbestr. 37  
75217 Birkenfeld  
Germany

Phone: +49 7082 7916-0

Fax: +49 7082 7916-999

[info@stratec.com](mailto:info@stratec.com)

[www.stratec.com](http://www.stratec.com)